Insmed Inc. has completed patient enrollment in its Phase II study of Arikace (liposomal amikacin for inhalation) for patients with recalcitrant nontuberculous mycobacterial (NTM) lung disease in the U.S. and Canada. Arikace has received Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the treatment of NTM lung infections. Ninety patients will participate in the trial. The company has concluded that the study is sufficiently powered to achieve...